CDK4 and breast carcinoma: To evaluate the proportion of MPM patients that would be potentially responsive or intrinsically resistant to CDK4/6 inhibition, we determined the CDK4 modification profile from frozen MPM tumours and normal pleura samples (Table S8A) as investigated previously in breast cancer [51].